Japanese Ministry Recommends Approval For J&J, GSK Drugs; Takeda Actos/Alogliptin Combo Missing
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare has recommended 10 drugs for marketing approval; these include new drugs from Johnson & Johnson, Eli Lilly, GlaxoSmithKline and Nippon Medi-Physics
You may also be interested in...
Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China
Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications